1252 GMT - Bayer sees its pharmaceutical business at a turning point, with recent drug launches expected to balance out a hit from patent expirations this year, divisional head Stefan Oelrich says in a call with reporters. "We have now entered the last year of what we are calling our resilience phase," Oelrich says. Sales of Nubeqa cancer drug and Kerendia kidney medicine are expected to grow about 50% this year at constant currency, he says. Overall, the German company expects full-year sales at its pharma division to be flat or grow up to 3% at constant currency, with a stronger performance in the second half, before returning to mid single percentage digit growth in 2027, Oelrich says. Shares fall 3.6%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 04, 2026 07:52 ET (12:52 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.